Form 4: Sana Biotechnology Director Robert Nelsen Granted 80,000 Stock Options

Sana Biotechnology, Inc. Director and 10% owner Robert Nelsen was granted 80,000 stock options with an exercise price of $2.55, vesting in 2026.

Summary

• Robert Nelsen, a Director and 10% Owner of Sana Biotechnology, Inc. (SANA), was granted 80,000 stock options.
• The transaction date for this grant was June 5, 2025.
• Each stock option has an exercise price of $2.55.
• The options vest and become exercisable as to 100% of the underlying shares on the earlier of June 5, 2026, or immediately prior to Sana's 2026 annual meeting of stockholders, contingent on continuous service.
• The options have an expiration date of June 4, 2035.
• Following this transaction, Robert Nelsen directly beneficially owns 80,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director and significant shareholder is generally viewed as a neutral to slightly positive event, as it aligns the insider's financial interests with the long-term success of the company, potentially fostering greater commitment and performance.

Positives

• The grant of stock options to a director and significant shareholder, Robert Nelsen, aligns his interests with the long-term performance and success of Sana Biotechnology, Inc.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic outlook, as it is solely a disclosure of an insider transaction.

Industry Context

The granting of stock options to directors and key personnel is a common practice in the biotechnology industry, serving as a form of equity compensation to incentivize long-term commitment and align management interests with shareholder value creation. This transaction is a routine disclosure of such compensation.

Comparison to Industry Standards

• The grant of stock options as a form of equity compensation to directors is a standard practice across the biotechnology and broader corporate sectors, aiming to align the interests of key individuals with the company's long-term performance.
• The vesting schedule, contingent on continuous service, is typical for such grants, ensuring retention and sustained engagement.

Corporate Governance

Related Party Transactions

• The grant of stock options to Robert Nelsen, who is both a Director and a 10% Owner, constitutes a related party transaction, which is a standard form of compensation for board members and significant stakeholders.

Stakeholder Impact

• Shareholders: The grant aligns the interests of a significant director and shareholder with the company's long-term performance, potentially leading to more aligned decision-making aimed at increasing shareholder value.
• Employees: While not directly impacting all employees, such grants are part of a broader compensation philosophy that can attract and retain talent.

Next Steps

• The stock options will vest on the earlier of June 5, 2026, or immediately prior to the 2026 annual meeting of stockholders, provided Robert Nelsen continues his service to Sana Biotechnology, Inc.

Key Dates

Keywords

Sana Biotechnology, SANA, Stock Options, Insider Transaction, Director Compensation, Equity Grant, Form 4, Biotechnology